Geron Corp

GERNNASDAQ • USD
0.98 USD
↗ 0.04 (4.05%)🟢LIVE (AS OF 12:46 PM EST)
🟢Market: OPEN

Geron Corp (GERN) trades at $0.98 per share. Technicals currently rate "Sell" while our fundamental analysis reads "Neutral". Notable factors include a concerning Altman Z-Score in the distress zone, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Nov 16, 2026.

Open?$0.96
High?$0.99
Low?$0.95
Prev. Close?$0.94
Volume?8.6M
Avg. Volume?14.3M
VWAP?$0.98
Rel. Volume?0.60x
Bid / Ask
Bid?$0.95 × 500
Ask?$0.98 × 200
Spread?$0.03
Midpoint?$0.96
Valuation & Ratios
Market Cap?605.6M
Shares Out?644.2M
Float?626.7M
Float %?97.6%
P/E Ratio?N/A
P/B Ratio?2.67
EPS?-$0.07
Dividend?0.00%
Ex-Dividend?N/A
RelatedALKS
News
Profile
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Employees
258
Market Cap
606.8M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
1996-07-31
Address
919 EAST HILLSDALE BOULEVARD
FOSTER CITY, CA 94404
Phone: (650) 473-7700
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
0
Momentum?
73
Short Sent.?
65
Piotroski F-Score?4/9Mixed
Altman Z-Score?-2.66Distress
Confidence?54%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?10.68%High
Short Interest?67.0M
Days to Cover?3.9
Free Float626.7M
Avg Daily Volume17.1M
Settlement Date2026-10-30
Financial Health
Current Ratio?6.31Strong
Quick Ratio?4.61Strong
Cash Ratio?0.93Adequate
Debt/Equity?1.10Moderate
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
92/100
P/E?
N/A▾
P/B?
Peers
100
S&P
61
2.67CHEAP▾
P/S?
Peers
100
S&P
54
2.78CHEAP▾
P/FCF?
N/A▾
EV/EBITDA?
Peers
100
S&P
97
-51.8CHEAP▾
EV/Sales?
Peers
100
S&P
52
3.61FAIR▾
Returns & Efficiency
ROE?
S&P
8
-21.1%WEAK▾
ROA?
S&P
3
-9.1%WEAK▾
Cash Flow & Enterprise
FCF?$-91162000
Enterprise Value?$785.9M
Fundamentals ratios updated end of day